about
Poly (methyl vinyl ether-co-maleic acid) - Pectin Based Hydrogel-Forming Systems: Gel, Film, and Microneedles.Tryptophan-tryptophan energy transfer and classification of tryptophan residues in proteins using a therapeutic monoclonal antibody as a model.Host-Guest Complexes of Carboxylated Pillar[n]arenes With Drugs.Design of therapeutic proteins with enhanced stability.Laboratory Scale Production and Purification of a Therapeutic Antibody.The state-of-play and future of antibody therapeutics.Lack of a synergistic effect of arginine-glutamic acid on the physical stability of spray-dried bovine serum albumin.Biobetters From an Integrated Computational/Experimental Approach.Global kinetic analysis of seeded BSA aggregation.Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopyRational design of rabies vaccine formulation for enhanced stability.Nile Red fluorescence spectrum decomposition enables rapid screening of large protein aggregates in complex biopharmaceutical formulations like influenza vaccines.N-Methylphthalimide-substituted benzimidazolium salts and PEPPSI Pd-NHC complexes: synthesis, characterization and catalytic activity in carbon-carbon bond-forming reactions.Predictive tools for stabilization of therapeutic proteins.Design and application of antibody cysteine variants.Femtosecond electron-transfer reactions in mono- and polynucleotides and in DNA.Energy migration in novel pH-triggered self-assembled beta-sheet ribbons.Crimean-Congo Hemorrhagic Fever: A bibliometric assessment of the literature.Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry.The effect of deuterium oxide on the conformational stability and aggregation of bovine serum albumin.Benzimidazolium-based novel silver N-heterocyclic carbene complexes: synthesis, characterisation and in vitro antimicrobial activity.Prediction of protein binding regions.Ionic liquids as biocompatible stabilizers of proteins.Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacyEvaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregationA screening tool for therapeutic monoclonal antibodies: Identifying the most stable protein and its best formulation based on thioflavin T bindingGlycosylation influences on the aggregation propensity of therapeutic monoclonal antibodiesPalladium N-Heterocyclic Carbene Complexes: Synthesis from Benzimidazolium Salts and Catalytic Activity in Carbon-carbon Bond-forming ReactionsCurrent Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and FormulationDemonstration of In Vitro Host-Guest Complex Formation and Safety of para-Sulfonatocalix[8]arene as a Delivery Vehicle for Two Antibiotic DrugsPreparation-free method can enable rapid surfactant screening during industrial processing of influenza vaccinesCholine ionic liquid enhances the stability of Herceptin® (trastuzumab)Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles
P50
Q30313228-95B18C64-4C49-4DBE-890E-4F57117844ACQ30394338-C422322B-79F3-47FA-8900-22E6A00CECB1Q31138792-54A05F70-E0AA-4D8E-8A95-46186A03B4CCQ37274488-54F7CFE4-F652-45A9-B2A6-482014B04B6CQ38716755-807DD33F-4D15-40C9-B29A-C9A11E741AB9Q38727682-7639829A-10F2-4593-9F98-5D0503BD20E6Q38865450-ACA7D881-3863-48BB-A627-3884DEC58475Q39127424-F178600E-8E44-407D-9D04-7D40AD28674EQ39926161-7704FF5E-80C2-46E3-A7C7-5D5DB53DBD52Q39978716-5BF4DA6A-7CD8-4DBC-880A-811289B6E8E5Q40158607-167B2232-2CB7-4433-A2C8-6C39F3FA8F47Q40213136-700A76E8-353C-4751-B5A4-3215C27274D3Q42118372-CEC22E16-916B-44E1-A5A8-8AF17EBD4F08Q42156173-43B77F53-39F3-420B-ACFD-BC8FBD417CB6Q43187230-51900440-A909-45F0-97A0-D0287252E17EQ43983765-3A3F3CFA-C556-49B9-9E43-7A2D37FD7DDDQ44716616-BD592AC9-E451-4B4C-9782-4C4894DD3309Q46711984-AE41F440-143A-4976-B371-E3DC7C9290C7Q47607365-3D38AEFB-6B1E-44FF-86EA-64134BFC1BC9Q51290482-C6A906F3-E302-4D21-B973-044605AA2866Q53189570-7ACDD1E9-D5A3-46C1-98CD-9EACCF56FBB1Q54615864-1C7C8227-85B7-4425-9BF2-BD8FCDCF5322Q55298632-9849C2C3-1C3B-48EC-9E3C-2943F0AB24E8Q64072797-3B69E43A-770B-40CD-BB2A-808BB547DEE9Q83300093-4A409345-244D-4763-88BC-BD547289412AQ85003133-38F118FB-33D5-4422-8F02-9509BDDB1635Q85200678-1F319CF2-9C55-4E58-AD0C-A7C688050126Q88709012-35C8CFD4-0CD4-4008-90B0-0B5EEABD85F6Q90212011-CB7E3A68-1509-4146-ABD3-2FF20C21769DQ91231449-DD127343-AF94-493E-9BBC-B0C9F2B98441Q91236334-BA3C41D3-1AB5-4159-B143-7C7EC51AAEA8Q91277345-1C37AF00-07B6-41A3-BD0E-D53BDF8EA1E7Q92990066-EBD3E6D0-E985-4705-9B2B-8854397E198C
P50
description
researcher ORCID ID=0000-0003-1310-9534
@en
name
Veysel Kayser
@en
Veysel Kayser
@nl
type
label
Veysel Kayser
@en
Veysel Kayser
@nl
prefLabel
Veysel Kayser
@en
Veysel Kayser
@nl
P106
P31
P496
0000-0003-1310-9534